imetelstat for transfusion-dependent r/r mds
Published 3 years ago • 670 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:00
imetelstat in heavily-transfused lower-risk r/r mds
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
9:38
imetelstat provides durable transfusion independence in lower risk mds group
-
24:00
managing indolent systemic mastocytosis: a multidisciplinary case review
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
3:28
preclinical studies of tasquinimod in mds: in vitro and in vivo investigations
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
1:57
enhancing clinical care in lr-mds: managing symptomatic/transfusion-dependent anemia
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond